ID: MRFR/MED/0909-HCR | 85 Pages | Author: Kinjoll Dey | March 2024
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.1 Definition
2.2 Scope of the Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Cerebral Vasospasm Market, by Diagnosis
6.1 Introduction
6.2 CT scan
6.3 Computed Tomography Angiography (CTA)
6.4 Digital Subtraction Angiography (DSA)
6.5 Magnetic Resonance Angiography (MRA)
6.6 Transcranial Doppler (TCD)
Chapter 7. Global Cerebral Vasospasm Market, by Treatment
7.1 Introduction
7.2 Nimodipine
7.3 Triple-H therapy
7.4 Balloon Angioplasty
7.5 Vasopressors
7.6 Inotropes
7.7 Thrombolytic Agents
7.8 Anti-inflammatory Agents
Chapter 8. Global Cerebral Vasospasm Market, by End-Users
8.1 Introduction
8.2 Hospitals and Clinics
8.3 Ambulatory Surgical Centers
8.4 Trauma Centers
8.5 Emergency Departments
8.6 Others
Chapter 9. Global Cerebral Vasospasm Market, by Region
9.1 Introduction
9.2 America
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 Republic of Korea
9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.3 Oman
9.5.4 Kuwait
9.5.5 Qatar
9.5.6 Rest of the Middle East & Africa
Chapter 10. Company Landscape
10.1 Introduction
10.2 Market Share Analysis
10.3 Key Development & Strategies
10.3.1 Key Developments
Chapter 11 Company Profiles
11.1 Headsense Medical Ltd
11.1.1 Company Overview
11.1.2 Type Overview
11.1.3 Financials
11.2.4 Key Developments
11.1.5 SWOT Analysis
11.2 B. Braun Melsungen AG
11.2.1 Company Overview
11.2.2 Type Overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Minnetronix, Inc
11.3.1 Company Overview
11.3.2 Type Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 Bristol-Myers Squibb Company
11.4.1 Company Overview
11.4.2 Type/Business Segment Overview
11.4.3 Financial Overview
11.4.4 Key Development
11.4.5 SWOT Analysis
11.5 Boehringer Ingelheim GmbH
11.5.1 Company Overview
11.5.2 Type Overview
11.5.3 Financial overview
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.6 H. Lundbeck A/S
11.6.1 Company Overview
11.6.2 Type Overview
11.6.3 Financial Overview
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.7 Koninklijke Philips N.V
11.7.1 Overview
11.7.2 Type Overview
11.7.3 Financials
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 SIEMENS AG
11.8.1 Overview
11.8.2 Type Overview
11.8.3 Financials
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.9 Edge Therapeutics, Inc.
11.9.1 Overview
11.9.2 Type Overview
11.9.3 Financials
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.10 GE Healthcare
11.10.1 Overview
11.10.2 Type Overview
11.10.3 Financials
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.11 Actelion Pharmaceuticals Ltd.
11.11.1 Overview
11.11.2 Type Overview
11.11.3 Financials
11.11.4 Key Developments
11.11.5 SWOT Analysis
11.12 Others
Chapter 12 Appendix
LIST OF TABLES
Table 1 Global Cerebral Vasospasm Market Industry Synopsis, 2023-2032
Table 2 Global Cerebral Vasospasm Market Estimates & Forecast, 2023-2032, (USD Million)
Table 3 Global Cerebral Vasospasm Market, by Region, 2023-2032, (USD Million)
Table 4 Global Cerebral Vasospasm Market, by Diagnosis, 2023-2032, (USD Million)
Table 5 Global Cerebral Vasospasm Market, by Treatment, 2023-2032, (USD Million)
Table 6 Global Cerebral Vasospasm Market, by End-User, 2023-2032, (USD Million)
Table 7 North America: Prescribed Health Apps Market, by Diagnosis, 2023-2032, (USD Million)
Table 8 North America: Cerebral Vasospasm Market, by Treatment, 2023-2032, (USD Million)
Table 9 North America: Cerebral Vasospasm Market, by End-User, 2023-2032, (USD Million)
Table 10 US: Cerebral Vasospasm Market, by Diagnosis, 2023-2032, (USD Million)
Table 11 US: Cerebral Vasospasm Market, by Treatment, 2023-2032, (USD Million)
Table 12 US: Cerebral Vasospasm Market, by End-User, 2023-2032, (USD Million)
Table 13 Canada: Cerebral Vasospasm Market, by Diagnosis, 2023-2032, (USD Million)
Table 14 Canada: Cerebral Vasospasm Market, by Treatment, 2023-2032, (USD Million)
Table 15 Canada: Cerebral Vasospasm Market, by End-User, 2023-2032, (USD Million)
Table 16 South America: Cerebral Vasospasm Market, by Diagnosis, 2023-2032, (USD Million)
Table 17 South America: Cerebral Vasospasm Market, by Treatment, 2023-2032, (USD Million)
Table 18 South America: Cerebral Vasospasm Market, by End-User, 2023-2032, (USD Million)
Table 19 Europe: Cerebral Vasospasm Market, Diagnosis, 2023-2032, (USD Million)
Table 20 Europe: Cerebral Vasospasm Market, by Treatment, 2023-2032, (USD Million)
Table 21 Europe: Cerebral Vasospasm Market, by End-User, 2023-2032, (USD Million)
Table 22 Western Europe: Cerebral Vasospasm Market, by Diagnosis, 2023-2032, (USD Million)
Table 23 Western Europe: Cerebral Vasospasm Market, by Treatment, 2023-2032, (USD Million)
Table 24 Western Europe: Cerebral Vasospasm Market, by End-User, 2023-2032, (USD Million)
Table 25 Eastern Europe: Cerebral Vasospasm Market, by Diagnosis, 2023-2032, (USD Million)
Table 26 Eastern Europe: Cerebral Vasospasm Market, by Treatment, 2023-2032, (USD Million)
Table 27 Eastern Europe: Cerebral Vasospasm Market, by End-User, 2023-2032, (USD Million)
Table 28 Asia-Pacific: Cerebral Vasospasm Market, by Diagnosis, 2023-2032, (USD Million)
Table 29 Asia-Pacific: Cerebral Vasospasm Market, by Treatment, 2023-2032, (USD Million)
Table 30 Asia-Pacific: Cerebral Vasospasm Market, by End-User, 2023-2032, (USD Million)
Table 31 Middle East & Africa: Cerebral Vasospasm Market, by Diagnosis, 2023-2032, (USD Million)
Table 32 Middle East & Africa: Cerebral Vasospasm Market, by Treatment, 2023-2032, (USD Million)
Table 33 Middle East & Africa: Cerebral Vasospasm Market, by End-User, 2023-2032, (USD Million)
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation for the Global Cerebral Vasospasm Market
Figure 3 Market Dynamics for the Global Cerebral Vasospasm Market
Figure 4 Global Cerebral Vasospasm Market Share, by Diagnosis 2020
Figure 6 Global Cerebral Vasospasm Market Share, by Treatment, 2020
Figure 6 Global Cerebral Vasospasm Market Share, by End-User, 2020
Figure 7 Global Cerebral Vasospasm Market Share, by Region, 2020
Figure 8 North America Cerebral Vasospasm Market Share, by Country, 2020
Figure 9 Europe Prescribed Health Apps Share, by Country, 2020
Figure 10 Asia-Pacific Cerebral Vasospasm Market Share, by Country, 2020
Figure 11 Middle East & Africa Cerebral Vasospasm Market Share, by Country, 2020
Figure 12 Global Cerebral Vasospasm Market: Company Share Analysis, 2020 (%)
Figure 13 Headsense Medical Ltd: Key Financials
Figure 14 Headsense Medical Ltd: Segmental Revenue
Figure 15 Headsense Medical Ltd: Geographical Revenue
Figure 16 B. Braun Melsungen AG: Key Financials
Figure 17 B. Braun Melsungen AG: Segmental Revenue
Figure 18 B. Braun Melsungen AG: Geographical Revenue
Figure 19 Minnetronix, Inc: Key Financials
Figure 20 Minnetronix, Inc: Segmental Revenue
Figure 21 Minnetronix, Inc: Geographical Revenue
Figure 22 Bristol-Myers Squibb Company: Key Financials
Figure 23 Bristol-Myers Squibb Company: Segmental Revenue
Figure 24 Bristol-Myers Squibb Company: Geographical Revenue
Figure 25 Boehringer Ingelheim GmbH: Key Financials
Figure 26 Boehringer Ingelheim GmbH: Segmental Revenue
Figure 27 Boehringer Ingelheim GmbH: Geographical Revenue
Figure 28 H. Lundbeck A/S: Key Financials
Figure 29 H. Lundbeck A/S: Segmental Revenue
Figure 30 H. Lundbeck A/S: Geographical Revenue
Figure 31 Koninklijke Philips N.V: Key Financials
Figure 32 Koninklijke Philips N.V: Segmental Revenue
Figure 33 Koninklijke Philips N.V: Geographical Revenue
Figure 34 SIEMENS AG: Key Financials
Figure 35 SIEMENS AG: Segmental Revenue
Figure 36 SIEMENS AG: Geographical Revenue
Figure 37 Edge Therapeutics, Inc.: Key Financials
Figure 38 Edge Therapeutics, Inc.: Segmental Revenue
Figure 39 Edge Therapeutics, Inc.: Geographical Revenue
Figure 40 GE Healthcare: Key Financials
Figure 41 GE Healthcare: Segmental Revenue
Figure 42 GE Healthcare: Geographical Revenue
Figure 43 Actelion Pharmaceuticals Ltd.: Key Financials
Figure 44 Actelion Pharmaceuticals Ltd.: Segmental Revenue
Figure 45 Actelion Pharmaceuticals Ltd.: Geographical Revenue
Cerebral Vasospasm Market Segmentation
Cerebral Vasospasm Diagnosis Outlook (USD Billion, 2018-2032)
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography
Transcranial Doppler
Cerebral Vasospasm Treatment Outlook (USD Billion, 2018-2032)
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors
Inotropes
Thrombolytic Agents
Anti-Inflammatory Agents
Cerebral Vasospasm End User Outlook (USD Billion, 2018-2032)
Hospitals
Clinics
Ambulatory surgical centers
Trauma Centers
Emergency Departments
Others
Cerebral Vasospasm Regional Outlook (USD Billion, 2018-2032)
North America Outlook (USD Billion, 2018-2032)
North America Cerebral Vasospasm by Diagnosis
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography,
Transcranial Doppler
North America Cerebral Vasospasm by Treatment
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors, Inotropes,
Thrombolytic Agents,
Anti-Inflammatory Agents
North America Cerebral Vasospasm by End User
Hospitals
Clinics
Ambulatory surgical centers,
Trauma Centers,
Emergency Departments,
Others
US Outlook (USD Billion, 2018-2032)
US Cerebral Vasospasm by Diagnosis
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography,
Transcranial Doppler
US Cerebral Vasospasm by Treatment
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors,
Inotropes,
Thrombolytic Agents,
Anti-Inflammatory Agents
US Cerebral Vasospasm by End User
Hospitals
Clinics
Ambulatory surgical centers,
Trauma Centers,
Emergency Departments,
Others
CANADA Outlook (USD Billion, 2018-2032)
CANADA Cerebral Vasospasm by Diagnosis
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography,
Transcranial Doppler
CANADA Cerebral Vasospasm by Treatment
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors,
Inotropes,
Thrombolytic Agents,
Anti-Inflammatory Agents
CANADA Cerebral Vasospasm by End User
Hospitals
Clinics
Ambulatory surgical centers,
Trauma Centers,
Emergency Departments,
Others
Europe Outlook (USD Billion, 2018-2032)
Europe Cerebral Vasospasm by Diagnosis
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography,
Transcranial Doppler
Europe Cerebral Vasospasm by Treatment
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors,
Inotropes,
Thrombolytic Agents,
Anti-Inflammatory Agents
Europe Cerebral Vasospasm by End User
Hospitals
Clinics
Ambulatory surgical centers,
Trauma Centers,
Emergency Departments,
Others
Germany Outlook (USD Billion, 2018-2032)
Germany Cerebral Vasospasm by Diagnosis
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography,
Transcranial Doppler
Germany Cerebral Vasospasm by Treatment
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors,
Inotropes,
Thrombolytic Agents,
Anti-Inflammatory Agents
Germany Cerebral Vasospasm by End User
Hospitals
Clinics
Ambulatory surgical centers,
Trauma Centers,
Emergency Departments,
Others
France Outlook (USD Billion, 2018-2032)
France Cerebral Vasospasm by Diagnosis
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography,
Transcranial Doppler
France Cerebral Vasospasm by Treatment
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors,
Inotropes,
Thrombolytic Agents,
Anti-Inflammatory Agents
France Cerebral Vasospasm by End User
Hospitals
Clinics
Ambulatory surgical centers,
Trauma Centers,
Emergency Departments,
Others
UK Outlook (USD Billion, 2018-2032)
UK Cerebral Vasospasm by Diagnosis
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography,
Transcranial Doppler
UK Cerebral Vasospasm by Treatment
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors,
Inotropes,
Thrombolytic Agents,
Anti-Inflammatory Agents
UK Cerebral Vasospasm by End User
Hospitals
Clinics
Ambulatory surgical centers,
Trauma Centers,
Emergency Departments,
Others
ITALY Outlook (USD Billion, 2018-2032)
ITALY Cerebral Vasospasm by Diagnosis
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography,
Transcranial Doppler
ITALY Cerebral Vasospasm by Treatment
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors,
Inotropes,
Thrombolytic Agents,
Anti-Inflammatory Agents
ITALY Cerebral Vasospasm by End User
Hospitals
Clinics
Ambulatory surgical centers,
Trauma Centers,
Emergency Departments,
Others
SPAIN Outlook (USD Billion, 2018-2032)
Spain Cerebral Vasospasm by Diagnosis
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography,
Transcranial Doppler
Spain Cerebral Vasospasm by Treatment
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors,
Inotropes,
Thrombolytic Agents,
Anti-Inflammatory Agents
Spain Cerebral Vasospasm by End User
Hospitals
Clinics
Ambulatory surgical centers,
Trauma Centers,
Emergency Departments,
Others
Rest Of Europe Outlook (USD Billion, 2018-2032)
Rest Of Europe Cerebral Vasospasm by Diagnosis
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography,
Transcranial Doppler
REST OF EUROPE Cerebral Vasospasm by Treatment
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors,
Inotropes,
Thrombolytic Agents,
Anti-Inflammatory Agents
REST OF EUROPE Cerebral Vasospasm by End User
Hospitals
Clinics
Ambulatory surgical centers,
Trauma Centers,
Emergency Departments,
Others
Asia-Pacific Outlook (USD Billion, 2018-2032)
Asia-Pacific Cerebral Vasospasm by Diagnosis
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography,
Transcranial Doppler
Asia-Pacific Cerebral Vasospasm by Treatment
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors,
Inotropes,
Thrombolytic Agents,
Anti-Inflammatory Agents
Asia-Pacific Cerebral Vasospasm by End User
Hospitals
Clinics
Ambulatory surgical centers,
Trauma Centers,
Emergency Departments,
Others
China Outlook (USD Billion, 2018-2032)
China Cerebral Vasospasm by Diagnosis
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography,
Transcranial Doppler
China Cerebral Vasospasm by Treatment
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors,
Inotropes,
Thrombolytic Agents,
Anti-Inflammatory Agents
China Cerebral Vasospasm by End User
Hospitals
Clinics
Ambulatory surgical centers,
Trauma Centers,
Emergency Departments,
Others
Japan Outlook (USD Billion, 2018-2032)
Japan Cerebral Vasospasm by Diagnosis
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography,
Transcranial Doppler
Japan Cerebral Vasospasm by Treatment
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors,
Inotropes,
Thrombolytic Agents,
Anti-Inflammatory Agents
Japan Cerebral Vasospasm by End User
Hospitals
Clinics
Ambulatory surgical centers,
Trauma Centers,
Emergency Departments,
Others
India Outlook (USD Billion, 2018-2032)
India Cerebral Vasospasm by Diagnosis
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography,
Transcranial Doppler
India Cerebral Vasospasm by Treatment
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors,
Inotropes,
Thrombolytic Agents,
Anti-Inflammatory Agents
India Cerebral Vasospasm by End User
Hospitals
Clinics
Ambulatory surgical centers,
Trauma Centers,
Emergency Departments,
Others
Australia Outlook (USD Billion, 2018-2032)
Australia Cerebral Vasospasm by Diagnosis
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography,
Transcranial Doppler
Australia Cerebral Vasospasm by Treatment
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors,
Inotropes,
Thrombolytic Agents,
Anti-Inflammatory Agents
Australia Cerebral Vasospasm by End User
Hospitals
Clinics
Ambulatory surgical centers,
Trauma Centers,
Emergency Departments,
Others
Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)
Rest of Asia-Pacific Cerebral Vasospasm by Diagnosis
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography,
Transcranial Doppler
Rest of Asia-Pacific Cerebral Vasospasm by Treatment
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors,
Inotropes,
Thrombolytic Agents,
Anti-Inflammatory Agents
Rest of Asia-Pacific Cerebral Vasospasm by End User
Hospitals
Clinics
Ambulatory surgical centers,
Trauma Centers,
Emergency Departments,
Others
Rest of the World Outlook (USD Billion, 2018-2032)
Rest of the World Cerebral Vasospasm by Diagnosis
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography,
Transcranial Doppler
Rest of the World Cerebral Vasospasm by Treatment
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors,
Inotropes,
Thrombolytic Agents,
Anti-Inflammatory Agents
Rest of the World Cerebral Vasospasm by End User
Hospitals
Clinics
Ambulatory surgical centers,
Trauma Centers,
Emergency Departments,
Others
Middle East Outlook (USD Billion, 2018-2032)
Middle East Cerebral Vasospasm by Diagnosis
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography,
Transcranial Doppler
Middle East Cerebral Vasospasm by Treatment
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors,
Inotropes,
Thrombolytic Agents,
Anti-Inflammatory Agents
Middle East Cerebral Vasospasm by End User
Hospitals
Clinics
Ambulatory surgical centers,
Trauma Centers,
Emergency Departments,
Others
Africa Outlook (USD Billion, 2018-2032)
Africa Cerebral Vasospasm by Diagnosis
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography,
Transcranial Doppler
Africa Cerebral Vasospasm by Treatment
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors,
Inotropes,
Thrombolytic Agents,
Anti-Inflammatory Agents
Africa Cerebral Vasospasm by End User
Hospitals
Clinics
Ambulatory surgical centers,
Trauma Centers,
Emergency Departments,
Others
Latin America Outlook (USD Billion, 2018-2032)
Latin America Cerebral Vasospasm by Diagnosis
Comoted tomography angiography
Digital subtraction Angiography
Magnetic Resonance Angiography,
Transcranial Doppler
Latin America Cerebral Vasospasm by Treatment
Nimodipine
Triple-H Therapy
Balloon Angioplasty
Vasopressors,
Inotropes,
Thrombolytic Agents,
Anti-Inflammatory Agents
Latin America Cerebral Vasospasm by End User
Hospitals
Clinics
Ambulatory surgical centers,
Trauma Centers,
Emergency Departments,
Others